CANBRIDGE-B released its interim results, with a profit of HKD 59.238 million during the period, turning from a loss to a profit year-on-year
I'm PortAI, I can summarize articles.
CANBRIDGE-B announced its interim results for the period ending June 30, 2025, with a profit of HKD 59.238 million, turning a profit compared to a loss in the same period last year. Revenue was HKD 22.248 million, a decrease of 50.33% year-on-year. The announcement pointed out that the decline in revenue was mainly due to the company's strategic focus on rare diseases, with the sales of Healan® in Taiwan being halted. Additionally, proactive inventory management was implemented in the first half of 2025, reducing the inventory of Mireb® . Earnings per share were HKD 0.14
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments